pharma QA – Page 38 – Pharma.Tips

Biologic charge variant shift (CEX) OOS after filling line intervention: patient safety impact assessment and batch disposition governance

Handling Biologic Charge Variant Shift (CEX) OOS Following Filling Line Intervention In the complex world of biologics manufacturing, the occurrence of out-of-specification (OOS) results, particularly with biologic charge variants (CEX),…

Carryover contamination risk in hormonal manufacturing: GMP investigation and containment strategy

Addressing Carryover Contamination Risks in Hormonal Manufacturing Through Thorough Investigation Carryover contamination in hormonal manufacturing poses significant risks not only to product quality but also to regulatory compliance and patient…

Biologic glycosylation shift (CQAs) outside trend during deviation investigation board review: viral safety and contamination response plan with inspection-ready evidence

Addressing Out-of-Trend Glycosylation Shifts in Biologics: An Essential Guide for Investigation and Compliance Deviation investigations in biologic manufacturing can present unique challenges, particularly when faced with out-of-trend glycosylation shifts that…

Carryover contamination risk during CPV review: GMP investigation and containment strategy

Understanding Carryover Contamination Risk During CPV Review: A GMP Investigation and Containment Strategy Carryover contamination poses a significant risk in pharmaceutical manufacturing, particularly during the commercial process verification (CPV) phase.…

Biologic sterility assurance gap during CPV trending review: how to document root cause when multiple unit operations are involved

Addressing Gaps in Biologic Sterility Assurance During CPV Trending Review Biologic sterility assurance is critical in the pharmaceutical manufacturing sector, particularly during the ongoing process verification (CPV) and trending analysis.…

Blend uniformity OOS in hormonal manufacturing: facility and HVAC risk mitigation

“`html Addressing Out-Of-Spec Blend Uniformity in Hormonal Manufacturing: Risk Mitigation Strategies In pharmaceutical manufacturing, especially within hormonal products, blend uniformity is critical for ensuring product quality and compliance with Good…

Biologic leachables signal from single-use systems after upstream media/raw material change: viral safety and contamination response plan with inspection-ready evidence

Responding to Signals of Biologic Leachables from Single-Use Systems Following Upstream Changes In the pharmaceutical manufacturing environment, particularly within the realm of biologics, the integrity and safety of products are…

Carryover contamination risk during inspection readiness: CAPA aligned to regulatory expectations

Addressing Carryover Contamination Risks During Inspection Readiness in Pharmaceutical Manufacturing Carryover contamination during pharmaceutical manufacturing can present significant challenges for organizations striving for compliance with inspection standards set by regulatory…

Biologic endotoxin OOS during deviation investigation board review: patient safety impact assessment and batch disposition governance

Assessing Biologic Endotoxin OOS in Deviation Investigations: A Comprehensive Approach When an Out of Specification (OOS) result for endotoxin levels in biological products is flagged during routine testing, it raises…

Blend uniformity OOS after cleaning cycle change: facility and HVAC risk mitigation

Addressing Blend Uniformity OOS Following Changes in Cleaning Cycles: A Practical Guide for Pharma Professionals In the competitive landscape of pharmaceutical manufacturing, maintaining product quality is of utmost importance. An…

Biologic upstream yield drop (OOT) during deviation investigation board review: viral safety and contamination response plan with inspection-ready evidence

Investigating a Drop in Biologic Upstream Yield: A Structured Approach for Deviation Review In the rapidly evolving world of biologics manufacturing, maintaining yield consistency is paramount. A drop in upstream…

Potency variability after cleaning cycle change: CAPA aligned to regulatory expectations

Addressing Potency Variability Triggered by Changes in Cleaning Cycles The pharmaceutical industry continually strives for optimal product consistency, especially concerning hormonal products that often require stringent potency and quality standards.…